Craig Crosson
Executive Director

For over 30 years my NIH-funded laboratory worked to understand the molecular and cellular events responsible several blinding diseases.  While these efforts formed the basis for new glaucoma therapeutics, the direct impact on improving the quality of life for afflicted individuals was limited.

In contrast, for almost 30 years OSOD has conducted hundreds of studies that help companies advance the development of new drugs and devices.  These studies have directly led to new approved treatments for conditions ranging from age-related macular degeneration to dry eye.  Collaborations we have established with the scientists, physicians and regulatory experts in academia and the development industry allows us to apply an extensive and comprehensive suite of services to ophthalmic drug and device development.  

Collaboration with individuals and organizations who are changing the quality of life for people around the world is a unique opportunity and I am honored to be part of this exceptional team.  Our shared passion can be simply stated by “how can we help.”